Leping Li | Oncology | Best Researcher Award

Posted on by Business Strategy

Prof. Leping Li – Oncology – Best Researcher Award

Alignment with Award Category

Professor Li Leping’s qualifications, research contributions, and leadership align seamlessly with the award category for which he is being considered. His expertise in gastrointestinal oncology and surgery, his successful integration of advanced technologies in medical practice, and his commitment to mentorship and education underscore the qualities that the award seeks to recognize. His career stands as a model for excellence in medicine, blending innovative research with transformative clinical practice.

 

Shandong Provincial Hospital | China

Profile

SCOPUS

🎓Early Academic Pursuits 

Education and Training

Li Leping’s journey into the medical field began with a strong academic foundation. He pursued his Bachelor’s Degree in Medicine at Shandong Medical University from 1982 to 1987. After earning his undergraduate degree, Li further advanced his education, obtaining his Master’s Degree in 1990 and later completing his Ph.D. in Medicine from Shandong University in 2004. These academic years shaped Li Leping into a highly skilled medical professional and laid the groundwork for his later accomplishments in the realm of digestive oncology and gastrointestinal surgery.

💼Professional Endeavors 

Academic Positions

Professor Li Leping’s professional career has spanned several decades, with continuous growth and leadership roles. He began his medical career in 1990 as an attending physician at the General Surgery Department of Shandong Provincial Hospital. Over the years, his expertise and contributions led to a series of promotions, and he became the Director of the General Surgery Department in 2007. In addition to this, Professor Li has held the position of Deputy Director of Shandong Provincial Hospital since 2017. His leadership in both clinical practice and hospital management has had a profound impact on Shandong Province’s medical community.

📚Contributions and Research Focus on Oncology

Professor Li Leping’s research contributions have been pivotal in the understanding and treatment of gastric and colorectal cancers. His specialization lies in molecular biology and its application in gastrointestinal cancer treatment, particularly in gastric and colorectal cancers. Li has been instrumental in investigating tumor-related molecular mechanisms and advancing diagnostic and therapeutic methods for these cancers. His leadership in numerous research projects, including one funded by the National Natural Science Foundation of China and several provincial projects, reflects his significant role in pushing forward scientific boundaries.

🏆Accolades and Recognition 

Li Leping’s dedication to the medical field has not gone unnoticed, and he has garnered numerous accolades throughout his career. In 2020, he was honored as the Fourth National Famous Doctor with Excellent Demeanor and was recognized for his contributions to the fight against the epidemic in Shandong. His work has earned him recognition as a Tai Shan Scholar, and he has been granted a Special Allowance from the State Council. These accolades, along with others such as the Second Prize of the Shandong Science and Technology Progress Award in 2021 and the Third Prize of the Chinese Medical Science and Technology Award in 2020, highlight his distinguished status in the medical and academic community.

🌍 Impact and Influence 

Community Impact

The impact of Professor Li Leping’s work extends far beyond the laboratory and hospital. His efforts in the integration of multi-disciplinary teams for the treatment of digestive system tumors have significantly changed the landscape of gastrointestinal oncology in Shandong Province. His leadership in establishing Shandong’s first MDT diagnostic and therapeutic platform for digestive tumors is an excellent example of his forward-thinking approach to modern healthcare.

🔮Legacy and Future Contributions 

As a visionary leader in gastrointestinal oncology and surgery, Li Leping’s legacy will likely endure through both his contributions to medical research and his role in transforming the medical education system. His commitment to the development of minimally invasive surgery and his efforts to train the next generation of surgeons have left an indelible mark on the field. Looking ahead, Professor Li is poised to continue making meaningful contributions to both the scientific community and patient care through ongoing research and mentorship.

Conclusion

In conclusion, Professor Li Leping’s career exemplifies the pinnacle of achievement in the fields of gastrointestinal surgery and digestive oncology. His academic excellence, leadership in research, and profound contributions to medical practice make him a deserving recipient of recognition in his field. With a robust legacy and continued influence, Professor Li Leping will no doubt inspire future generations of medical professionals and researchers to follow in his footsteps. His impact on both the local and national levels, as well as his ongoing dedication to advancing medical science, ensures that his work will continue to resonate for many years to come

📚Publications

Tumor microenvironment characteristics association with clinical outcome in patients with resected intestinal-type gastric cancer

Authors: C., Tian, Chunfang, H., Jing, Haiyan, F.A., Sinicrope, Frank A., … W., Song, Wei, D., Sha, Dan

Journals: Oncologist, 2024

Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer

Authors: H., Chen, Hao, C., Jing, Changqing, L., Shang, Liang, … W., Chong, Wei, L., Li, Leping

Journals: Cell Reports, 2024

Clinical features and molecular landscape of cuproptosis signature-related molecular subtype in gastric cancer

Authors: W., Chong, Wei, H., Ren, Huicheng, H., Chen, Hao, … C., Jing, Changqing, L., Li, Leping

Journals: iMeta, 2024

Clinical landscape and prognosis of patients with gastric cancer liver metastases: A nation-wide multicenter cohort study in China (RECORD study)

Authors: Y., Gao, Yunhe, H., Xi, Hongqing, L., Shang, Liang, … L., Li, Leping, L., Chen, Lin

Journals:Science Bulletin, 2024

Yu Hong Li | Gastrointestinal Cancer | Best Researcher Award

Posted on by Business Strategy

Prof. Dr. Yu Hong Li  – Gastrointestinal Cancer – Best Researcher Award

Sun yat-sen University | China

      Profile

Scopus

Orcid

📍Current Position

Professor Yuhong Li holds dual roles as a Professor and Chief Physician at the prestigious Sun Yat-sen University Cancer Center. In her current capacity, she leads clinical teams, contributes to innovative research, and mentors the next generation of medical professionals. Her position underscores her influence in medical oncology and her commitment to enhancing cancer care globally.

 

📝Publication Achievements

Professor Li’s contributions to medical literature are both prolific and impactful, featuring studies that drive advancements in oncology: Her co-authored paper on capecitabine maintenance therapy for metastatic colorectal cancer provided significant insights into treatment optimization (Ann of Oncol, 2016). She has explored tumor resistance mechanisms via circulating tumor DNA monitoring, furthering the understanding of colorectal cancer progression (Drug Resist Updat, 2022). Her 2024 TRICE trial publication revolutionized conversion therapy approaches for colorectal liver metastases (Plos Medicine, 2024). Other key studies include innovations in adjuvant chemotherapy efficacy (Theranostics, 2021) and insights into resistance to targeted therapies (Clin Cancer Res, 2011).

 

🔍Ongoing Research

Professor Li’s current focus is on developing personalized treatment strategies for colorectal cancer liver metastases. By integrating clinical trials with translational research, she aims to bridge the gap between laboratory discoveries and patient care. Her dynamic use of circulating tumor DNA to monitor therapeutic resistance showcases her innovative methodologies.

 

🔬 Research Interests

Her research interests span: Gastrointestinal tumors including colorectal, pancreatic, and bile duct cancers. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The interplay of immune checkpoint inhibitors with genetic mutations in liver metastases.

 

🎓Academic Background

Bachelor’s Degree in Clinical Medicine, Bengbu Medical College (1986–1991). Master’s Degree in Oncology, Sun Yat-sen University (1994–1997). Doctorate in Oncology, Sun Yat-sen University (2000–2003). Her robust academic journey laid the foundation for her expertise in oncology.

 

🏆Scholarships and Awards

While specific accolades are not listed, her academic progression and professional trajectory reflect a history of recognition for excellence.

 

🧬Bioinformatics 

Professor Li integrates bioinformatics in her research, particularly for: Dynamic monitoring of circulating tumor DNA, enabling real-time insights into tumor response. Analyzing genetic resistance patterns to improve therapeutic accuracy.

 

🌐Professional Associations 

Professor Li is likely affiliated with leading oncology and gastroenterology societies, enhancing her collaborative impact.

 

 📚Training & Workshops 

She has completed multiple Good Clinical Practice (GCP) certifications (2001, 2006, 2007), demonstrating her dedication to ethical and high-standard clinical trials.

 

🎤Oral Presentations and🗣️Thought Leadership 

As an esteemed researcher, Professor Li frequently presents at national and international forums, sharing her findings and contributing to global oncology discussions.

 

🧑‍🔬Tasks Completed as a Researcher 

Design and execution of clinical trials for gastrointestinal cancer therapies. Translational research bridging laboratory innovations to clinical applications. Publication of high-impact papers, influencing clinical practices worldwide.

 

🚀Success Factors 

Her success is attributed to: Dedication to patient care and research excellence. The ability to collaborate across disciplines to innovate solutions. A focus on mentorship and education, ensuring sustainability in medical advancements.

 

🧪Publications & Laboratory Experience

With a portfolio of groundbreaking publications, Professor Li’s laboratory experience focuses on experimental designs that translate into actionable clinical strategies.

 

🔍 Conclusion

Professor Yuhong Li’s contributions to medical oncology position her as a global leader in cancer research. Her unwavering commitment to personalized care, innovative methodologies, and clinical excellence makes her an ideal candidate for any Best Researcher Award. Her efforts not only push the boundaries of science but also bring tangible improvements to patients’ lives worldwide.

📚Publications

Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma

           Author: Wang, F., Wang, Y., Ren, C., … Li, S., Guo, G.

          Journal: Pancreatology

Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

           Author: Li, Z.-J., Pat Fong, W., Zhang, D.-S., … Li, Y.-H., Wang, D.-S.

          Journal: npj Precision Oncology

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

           Author: Wang, F., Jin, Y., Wang, M., … Zhao, Q., Xu, R.-H.

           Journal: Nature Medicine

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/ BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

           Author: Wang, D.-S., Ren, C., Li, S.-S., … Xu, R.-H., Li, Y.-H.

          Journal: PLoS Medicine

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

           Author: Sun, Y.-T., Lu, S.-X., Lai, M.-Y., … Yang, D.-J., Qiu, M.-Z.

          Journal: Cancer Immunology, Immunotherapy

 

DEROSA LISA | IMMUNOLOGY ONCOLOGY | Best Researcher Award

Posted on by Business Strategy

Assist Prof Dr. DEROSA LISA – IMMUNOLOGY ONCOLOGY – Best Researcher Award 

GUSTAVE ROUSSY | France

Author Profile 

Early Academic Pursuits 🎓

She, MD, PhD, began her academic journey with a deep passion for medicine and oncology. She completed her MD at Pisa University in 2008, followed by a qualifying examination and registration as a physician in Italy in 2009. He pursued a specialty in medical oncology at Pisa University, achieving board certification in 2014. Her dedication to advancing her knowledge led her to complete an M2 in Pharmacology, Clinical Trial in Oncology at Pisa University in 2015. She further enhanced her expertise with a European University Diploma in Translational and Clinical Research in Oncology (DUERTECC) from Paris-Sud University in 2016, and a University Diploma in Animal Experimentation from Sorbonne University in 2018.

In 2019, he earned her PhD in Immunology from Paris-Sud University. Her academic excellence was further recognized when she became an Associate Professor of Immunology at Paris-Saclay University in 2023.

 Professional Endeavors 💼

Her professional career is marked by her commitment to cancer research and patient care. She holds several key positions at the prestigious Gustave Roussy Cancer Center (GRCC) in Villejuif-Grand Paris, France. As the Clinical Director of the ClinicObiome Cancer Immunology Department, she oversees groundbreaking programs focused on the interplay between the gut microbiome and cancer immunotherapy. She also serves as a Senior Specialist in Medical Oncology and a Research Associate in the U1015 Cancer Immunology Department at GRCC.

In addition to her roles at GRCC, she is an Associate Professor of Immunology at the Medical School of Paris-Saclay University. Her specialty lies in tumor immunology and cancer immunotherapy, where she has made significant contributions since 2016.

Contributions and Research Focus on IMMUNOLOGY ONCOLOGY📚

Her research focuses on the immunosuppressive effects of antibiotics in cancer immunotherapy and the role of gut microbiota in regulating antitumor immunity. She has pioneered several concepts in this field, demonstrating how gut microbiota composition can influence the efficacy of immune checkpoint inhibitors. Her work has been widely published, with over 100 papers indexed on PubMed, including multiple contributions to high-impact journals such as Nature Medicine, Cell, and Cancer Discovery. Her impressive H-factor of 38 and 8,515 citations underscore her influence and the importance of her research in the scientific community.

Accolades and Recognition 🏆

Throughout her career, she has received numerous prestigious awards and honors, highlighting her contributions to oncology and immunology. Notable awards include multiple Merit Awards from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). In 2023, she received the Conquer Cancer Foundation ASCO Merit Award. Other significant recognitions include the Best Scientific Paper Award from European Urology in 2021 and the EATI Award in 2020.

 Impact and Influence 🌍

Her work has had a profound impact on the field of cancer immunotherapy. Her research on the gut microbiome’s role in cancer treatment has opened new avenues for understanding and enhancing the efficacy of immunotherapy. She leads the Microbiota-centered intervention program (ClinicObiome) at GRCC and co-directs significant clinical programs such as the RHU Clinical Program Grant “Immunolife” and the EU Program Grant “Oncobiome”. These programs aim to develop innovative strategies for cancer treatment based on her groundbreaking research.

 Legacy and Future Contributions 🔮

Her legacy in the field of oncology and immunology is marked by her pioneering research and significant contributions to cancer treatment. Her ongoing work continues to push the boundaries of medical science, offering new hope for cancer patients worldwide. As she advances in her career, she is poised to make even greater strides in understanding and leveraging the immune system’s role in cancer therapy. Her dedication to research, patient care, and education ensures that her impact will be felt for generations to come.

Notable Publications 

  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
  2. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
  3. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19
  4. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials
  5. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
  6. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
  7. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
  8. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
  9. Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage